

## Appointment of Non-Executive Director

**February 7, 2017** – InvitroCue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Dr Andreas Lindner as Non-Executive Director.

Dr Lindner is a senior executive with significant global experience across a range of industries including healthcare and technology. He was a founding partner of global healthcare company Medi-Globe, a supplier of equipment and services for minimally invasive surgery and urology, as well as hospital supplies. His experience also includes establishment of a private venture capital business, which invested across industries including technology, new media and internet. Most recently, Dr Lindner founded Health Complete, a material supply company specialising in highly efficient and biodegradable cleaning products. Dr Lindner has a PhD (Business) from Ludwig-Maximilian University of Munich.

In joining InvitroCue, Dr Lindner stated “I am delighted to join the InvitroCue board at such an exciting time for the company. InvitroCue’s technology has the potential to be a game changer in personalised oncology, and furthermore it has built a strong supply business with an impressive network of both customers and partners globally which also holds great appeal to me, and I believe will create significant value over time.”

Commenting on the appointment, InvitroCue Executive Director, Dr Steven Fang said, “We are delighted to welcome Dr Andreas Lindner to our board of directors at a time when we are transforming InvitroCue to form strategic partnerships and commercial alliances across multiple global markets. Dr Lindner has a demonstrated track record building high tech businesses in the healthcare space, and his unique skillset will be a major asset for our company moving forward.”

- ENDS -

**For more information, please contact:**

Martin D. Bach, VP Operations

T: +65 6460 0490

For personal use only



INVITROCUE™  
Transforming bioanalytics

martind.bach @invitrocue.com

### About Invitrocue

Invitrocue is a leading healthcare bio-analytic solutions including *in vitro* cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine). Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A\*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

For personal use only

InvitroCue Limited | ACN 009 366 009  
Level 2, 350 Kent Street, Sydney, NSW, 2000, Australia

